EUA for blood purifier for COVID-19 patientsMay 9, 2020
The US FDA issued an emergency use authorisation for Spectra Optia Apheresis System and Depuro D2000 Adsorption Cartridge devices, a blood purification system to treat patients 18 years of age or older with confirmed COVID-19 admitted to the ICU with confirmed or imminent respiratory failure.
The product works by reducing the amount of cytokines and other inflammatory mediators, i.e., small active proteins in the bloodstream that control a cell’s immune response by filtering the blood and returning the filtered blood to the patient. The proteins that are removed are typically elevated during infections and can be associated with a “cytokine storm” that occurs in some COVID-19 patients.
The FDA issued this authorization to Terumo BCT Inc. and Marker Therapeutics AG.